Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Revenue | N/A | N/A | $654.00K | $1.66M | $518.48K |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | $654.00K | $1.66M | $518.48K |
| Gross Margin | 0.00% | 0.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | $105.77M | $68.51M | $61.16M | $52.29M | $5.11M |
| Operating Income | $-105.77M | $-68.51M | $-60.51M | $-50.64M | $-4.59M |
| Operating Margin | 0.00% | 0.00% | -9252.14% | -3055.94% | -884.86% |
| Net Income | $-98.33M | $-66.39M | $-59.28M | $-50.62M | $-5.15M |
| Net Margin | 0.00% | 0.00% | -9063.76% | -3055.04% | -993.83% |
| EPS (Basic) | $-3.09 | $-2.49 | $-2.36 | $-2.01 | $-0.20 |
| EBITDA | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A |